Macrogenics Inc. (M55)
XDUS 
Summary
M55 Chart
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Macrogenics Inc. (M55) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Macrogenics Inc. ever had a stock split?
Macrogenics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Risser CEO | XDUS Exchange | US5560991094 ISIN |
| US Country | 293 Employees | - Last Dividend | - Last Split | 10 Oct 2013 IPO Date |
Overview
MacroGenics, Inc. is a seasoned biopharmaceutical entity based in Rockville, Maryland, United States, that specializes in discovering, developing, and bringing to market antibody-based therapeutics aimed at combating cancer. Since its inception in 2000, MacroGenics has focused on employing its proprietary technology to create novel treatments that offer hope to patients battling various cancer types. With a strong commitment to innovation and excellence, MacroGenics has established collaborations with notable industry players such as Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc., furthering its reach and impact within the biopharmaceutical field.
Products and Services
- MARGENZA (margetuximab-cmkb)
- Immuno-Oncology Product Candidates
- MGC018: An antibody-drug conjugate (ADC) targeting solid tumors expressing B7-H3.
- Enoblituzumab: A monoclonal antibody targeting B7-H3 to treat cancer.
- MGD024: A bispecific CD123 × CD3 DART (Dual-Affinity Re-Targeting) molecule designed to minimize cytokine-release syndrome for patients with hematologic malignancies.
- Other Therapeutic Candidates
- Lorigerlimab: A monoclonal antibody targeting PD-1 and CTLA-4 immune checkpoints.
- Tebotelimab: A tetravalent DART molecule for PD-1 and LAG-3.
- Retifanlimab: A programmed death receptor-1 (PD-1) targeting humanized monoclonal antibody.
- IMGC936: An ADC targeting ADAM9, a cell surface protein overexpressed in various solid tumor types.
- MGD014 and MGD020: DART molecules targeting human immunodeficiency virus (HIV) infected cells and CD3 on T cells.
- Teplizumab: Under development for treating type 1 diabetes.
- PRV-3279: A CD32B × CD79B DART molecule aimed at treating autoimmune diseases.
This product is an approved human epidermal growth factor receptor 2 (HER2) receptor antagonist, used in combination with chemotherapy, for treating adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens. MARGENZA represents a significant advancement in the treatment of this challenging cancer type, offering new hope to patients who have exhausted other therapeutic options.
MacroGenics' pipeline comprises several promising immuno-oncology product candidates in various development stages:
Beyond cancer treatment, MacroGenics is developing therapies targeting autoimmune diseases and infectious diseases, including:
